Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention
Thrombosis and Haemostasis · 2025-08 · 125 (08) · 802-813
DOI: 10.1055/a-2499-5458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 24.03.2025. Verfasst von Jeong Yoon Jang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Centre, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Ho…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Clopidogrel, Aspirin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Platelet- Thrombosis Research Group.
Abstract (Originalsprache)
To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI). Patients at high risks of both ischaemia and bleeding were eligible for inclusion. We excluded patients with any ischaemic and major bleeding complications during the mandatory period of dual antiplatelet therapy (DAPT). Clinical outcomes were evaluated in three groups of regimens, namely, clopidogrel monotherapy (CLPD), aspirin monotherapy (ASA), and DAPT group. The primary endpoint was a composite of all-cause death, myocardial infarction, stroke, or major bleeding for 12-month follow-up period. To balance characteristics according to antiplatelet strategies, stabilized inverse probability treatment weighting (IPTW) was conducted. After IPTW adjustment, CLPD group (N = 916) showed significantly lower rate of primary endpoint than DAPT group (N = 949) (hazard ratio [HR] = 2.09, 95% confidence interval [CI] = 1.22–3.60, p = 0.008), but there was no statistical difference between CLPD and ASA groups (N = 838) (HR = 1.46, 95% CI = 0.83–2.54, p = 0.187). Clinical benefits of CLPD over DAPT was mainly driven by the lower incidence of ischemic events (HR = 2.51, 95% CI 1.37–4.61; p = 0.003). Incidence of major bleeding did not differ among groups, but there was an increased bleeding tendency in DAPT group compared to CLPD group (HR = 2.51, 95% CI = 0.85–7.41, p = 0.096). For patients at high bleeding and ischaemic risk, especially undergoing complex PCI, clopidogrel monotherapy demonstrated a significant net clinical benefit compared to DAPT. Clopidogrel monotherapy showed numerical reductions of bleeding and ischaemic event rates compared to aspirin monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cardiovascular Centre, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
- Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Hospital, Jinju, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Republic of Korea.
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Cardiovascular Center, Department of Cardiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Jeong Yoon Jang, Young-Hoon Jeong, Moo Hyun Kim
Förderung
- Platelet- Thrombosis Research Group
Zitieren
APA
Jang, J. Y., Yu, G. I., Ahn, J., Bae, J. S., Cho, Y. H., Kang, M. G., Koh, J. S., Jeong, Y. H., Lee, S. Y., Kim, B. K., Joo, H. J., Lim, D. S., Chang, K., Song, Y. B., Ahn, S. G., Suh, J. W., Cho, J. R., Her, A. Y., Kang, J. H., …, & PTRG-DES Consortium Investigators (2025). Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 125(08), 802-813. https://doi.org/10.1055/a-2499-5458
Vancouver
Jang JY, Yu GI, Ahn J, Bae JS, Cho YH, Kang MG, et al. Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention. Thrombosis and Haemostasis. 2025;125(08):802-813. doi:10.1055/a-2499-5458
BibTeX
@article{Jang2025,
author = {Jang, Jeong Yoon and Yu, Ga-In and Ahn, Jongwha and Bae, Jae-Suck and Cho, Yun-Ho and Kang, Min-Gyu and Koh, Jin-Sin and Jeong, Young-Hoon and Lee, Sang Yeup and Kim, Byeong-Keuk and Joo, Hyung Joon and Lim, Do-Sun and Chang, Kiyuk and Song, Young Bin and Ahn, Sung Gyun and Suh, Jung-Won and Cho, Jung Rae and Her, Ae-Young and Kang, Jee-Hoon and Kim, Hyo-Soo and Kim, Moo Hyun and Shin, Eun-Seok and Park, Yongwhi and PTRG-DES Consortium Investigators, PTRG-DES Consortium Investigators},
title = {Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {08},
pages = {802--813},
doi = {10.1055/a-2499-5458}
}
EUVIMED